Erylosides from the Carribean Sponge Erylus formosus
Journal of Natural Products, 2007, Vol. 70, No. 2 177
Eryloside F3 (3): amorphous solid, 3.5 mg (0.0059% of dry weight);
[R]D25 -25.0 (c 0.10, MeOH); 1H and 13C NMR data, see Tables 1-3;
HR (+) ESTOFMS m/z 789.4390 [M + Na]+, calcd for C41H66O13Na
789.4401.
Eryloside F4 (4): amorphous solid, 6.0 mg (0.01% of dry weight);
[R]D25 -12.0 (c 0.10, MeOH); 1H and 13C NMR data, see Tables 1-3;
HR (+) ES TOF MS m/z 787.4272 [M + Na]+, calcd for C41H64O13Na
787.4245.
Eryloside M (5): amorphous solid, 11.0 mg (0.018% of dry weight);
[R]D25 -10.2 (c 0.25, MeOH); 1H and 13C NMR data, see Tables 1-3;
HR-MALDI-TOF MS m/z 919.5138 [M + Na]+, 875.4 [M + Na -
CO2]+, calcd for C47H76O16Na 919.5026.
was incubated additionally 10 min at 37 °C. The intensity of
fluorescence was measured at λex ) 485 nm, λem ) 620 nm.
A suspension of Ehrlich carcinoma cells (200 µL in each well of a
96-well microplate containing 20 µL solutions of tested compound)
was incubated for 1 h at 37 °C. Then 10 µL of Hoechst 33342 water
solution was added to each well (final concentration 5 µM). After 5
min of incubation at room temperature the fluorescence of the cell
suspension was measured at λex ) 355 nm and λem ) 460 nm. The
induction of chromatin condensation (early apoptosis) was determined
by comparison of fluorescence intensity of Hoechst 33342 (apoptotic
cells) and propidium iodide (necrotic cells) in the cell suspension.
Mouse lymphocytes (spleenocytes) were obtained from a mouse
spleen. For this purpose a spleen was isolated and cut with scissors
into small-sized slices in PBS (pH 7.4) and then pressed through nylon
gauze (280 mesh). The obtained suspension was washed twice in PBS
by centrifugation (2000 rpm, 10 min). The final concentration of cells
in the incubation medium was (2-5) × 106 cells/mL. A solution of
calcium green-1/AM (final concentration 10 µM) was added to the
suspension, and the cells were incubated with the fluorescent probe
during 60-90 min at 37 °C. Then the suspension of spleenocytes was
washed in PBS by a centrifugation at 1500 rpm, and 100 µL of the
suspension was placed in wells of a 96-well microplate including 10
µL solutions of tested compounds. The incubation was conducted during
5 min at 37 °C, and the intensity of the fluorescence was measured at
λex ) 485 nm, λem ) 518 nm. The intensity of the fluorescence in all
experiments was measured with a Fluoroscan Ascent (ThermoLab-
systems, Finland) fluorescent plate reader.23
Eryloside N (6): amorphous solid, 13.0 mg (0.022% of dry weight);
[R]D25 -14.0 (c 0.25, MeOH); 1H and 13C NMR data, see Tables 4, 5;
HR-MALDI-TOF MS m/z 905.4740 [M + Na]+, calcd for C46H74O16-
Na 905.4870, 861.5 [M + Na - CO2]+.
Eryloside O (7): amorphous solid, 21.0 mg (0.035% of dry weight);
[R]D -7.0 (c 0.25, MeOH); H and 13C NMR data, see Tables 4, 5;
HR-MALDI-TOF MS m/z 1092.5827 [M + Na]+, calcd for C54H76O87O20-
NNa 1092.5714.
25
1
Eryloside P (8): amorphous solid, 9.0 mg (0.015% of dry weight);
[R]D25 -10.2 (c 0.25, MeOH); 1H and 13C NMR data, see Tables 4, 5;
HR-MALDI-TOF MS m/z 1375.6443 [M + Na]+, calcd for C64H104O30-
Na 1375.6506.
Eryloside Q (9): amorphous solid, 34 mg (0.057% of dry weight);
[R]D25 -11.0 (c 0.25, MeOH); 1H and 13C NMR data, see Tables 4, 5;
HR-MALDI-TOF MS m/z 1361.6402 [M + Na]+, calcd for C63H102O30-
Na 1361.6349, 1317.5 [M + Na - CO2]+, 1185.5 [M + Na - CO2 -
C5H8O4]+.
Acknowledgment. This study was carried out in the framework of
a bilateral project between Pacific Institute of Bioorganic Chemistry
of the Russian Academy of Sciences (Russia) and Instituto di Chimica
Biomoleculare (ICB-CNR), Italy. The research described in this
publication was made possible in part by the Program of Presidium of
RAS “Molecular and Cell Biology” and a grant supporting leading
scientific schools.
Eryloside F (10): amorphous solid, 4.5 mg (0.0075% of dry weight);
[R]20D -41.0 (c 0.1, MeOH); HR-MALDI-TOF MS m/z 1361.6502 [M
+ Na]+, calcd for C63H102O30Na 1361.6349. 1H and 13C NMR spectra
were identical with those reported in the literature.4
Eryloside H (11): amorphous solid, 3.0 mg; [R]20 -11.2 (c 0.1,
D
MeOH); HR-MALDI-TOF MS m/z 1361.6502 [M + Na]+, calcd for
C63H102O30Na 1361.6349. 1H and 13C NMR spectra were identical with
those reported in the literature.5
Supporting Information Available: 2D NMR spectra of com-
pounds 1-9. This material is available free of charge via the Internet
at htpp://pubs.acs.org.
Acidic Hydrolysis of Erylosides F1-F4 (1-4). A solution of
compounds 1-4 (each 1.5 mg) in 2 N HCl (0.5 mL) was heated in a
stoppered reaction vial at 100 °C for 2 h. The water layer was extracted
with CHCl3 and then neutralized with Dowex (HCO3-). The residue
obtained after evaporation of the H2O layer was separated on an Agilent
ZORBAX carbohydrate analysis column (5 µm, 4.6 × 250 mm) eluting
with CH3CN-H2O (75:25) to yield 1.0 mg of D-galactose, [R]20D +79.0
References and Notes
(1) Carmely, Y.; Roll, M.; Kashman, Y. J. Nat. Prod. 1989, 52, 167-
170.
(2) D’Auria, M. V.; Paloma, L. G.; Riccio, R.; Debitus, C. Tetrahedron
1992, 48, 491-498.
(3) Gulavita, N. K.; Wright, A. E.; Kelly-Borges, M.; Longley, R. E.
Tetrahedron Lett. 1994, 35, 4299-4302.
(c 0.1, H2O) and 0.8 mg of L-arabinose, [R]20 +101.0 (c 0.08, H2O).
D
Acidic Hydrolysis Followed by GC Monosaccharide Analysis of
Eryloside O (7). A solution of compound 7 (3.5 mg) in 1 N TFA (1
mL) was heated in a stoppered reaction vial at 100 °C for 2 h. The
residue obtained after evaporation of the H2O layer was separated on
an Agilent ZORBAX carbohydrate analysis column (5 µm, 4.6 × 250
mm) eluting with CH3CN-H2O (75:25) to yield 1.0 mg of galactose,
0.7 mg of arabinose, and 0.8 mg of 2-N-acetylglucosamine. The
monosaccharides were treated with (-)-2-octanol (0.2 mL) in the
presence of trifluoroacetic acid (1 drop) in a stoppered reaction vial at
130 °C overnight. The mixtures were evaporated to dryness and
acetylated with Ac2O in pyridine. The acetylated (-)-2-octyl glycosides
were analyzed by GC using the corresponding authentic samples
prepared from D- and L-galactose, and D- and L-arabinose. Retention
time for the L-GlcNAc derivative was determined for (+)-2-octyl
glycoside of the corresponding D-sugar according to Leontein.20
Acidic Hydrolysis and GC Analysis of Monosaccharide Com-
position of Eryloside P (8). Compound 8 (6.5 mg) was hydrolyzed as
described above for erylosides F1-F4. The absolute configurations of
the monosaccharides were determined by GC of the acetylated (-)-
2-octyl glycosides using the corresponding authentic samples prepared
from D- and L-galactose, D- and L-arabinose, and D- and L-xylose.20
Bioassays. Ehrlich carcinoma cells were grown intraperitoneally in
albino mice, 18-20 g of weight. Cells were harvested on the seventh
to tenth day after inoculation and washed twice by centrifugation (450g,
10 min) in cold phosphate-buffered saline (PBS). Then 100 µL of the
cell suspension (final cell concentration (2-5) × 106 cells/mL) was
placed into wells of a 96-well microplate containing 10 µL solutions
of tested compounds. The incubation was conducted within 1 h at 37
°C. Then 10 µL of an aqueous solution of propidium iodide (final
concentration 2.5 µg/mL) was added to each well, and the microplate
(4) Stead, P.; Hiscox, S.; Robinson, P. S.; Pike, N. B.; Sidebottom, P.
J.; Roberts, A. D.; Taylor, N. L.; Wright, A. E.; Pomponi, S. A.;
Langley, D. Biorg. Med. Cem. Lett. 2000, 10, 661-664.
(5) Shin, J.; Lee, H. S.; Woo, L.; Rho, J. R.; Seo, Y.; Cho, K. W.; Sim,
C. J. J. Nat. Prod. 2001, 64, 767-771.
(6) Sandler, J. S.; Forsburg, S. L.; Faulkner, D. J. Tetrahedron 2005,
61, 1199-1206.
(7) Takada, K.; Matsunaga, S.; van Soest, R. W. V.; Fusetani, N. J. Nat.
Prod. 2002, 65, 411-413.
(8) Jaspars, M.; Crews, P. Tetrahedron Lett. 1994, 35, 7501-7504.
(9) Campagnuolo, C.; Fattorusso, E.; Taglialatela-Scafati, O. Tetrahedron
2001, 57, 4049-4055.
(10) Cheng, J. F.; Kobayashi, J.; Nakamura, H.; Ohizumi, Y.; Hirata, Y.;
Sasaki, T. J. Chem. Soc., Perkin Trans. 1988, 8, 2403-2406.
(11) Shoji, N.; Umeyama, A.; Motoki, S.; Arihara, S.; Ishida, T.; Nomoto,
K.; Kobayashi, J.; Takei, M. J. Nat. Prod. 1992, 55, 1682-1685.
(12) Takei, M.; Umeyama, A.; Shoji, N.; Arihara, S.; Endo, R. J. Pharm.
Sci. 1995, 84, 228-230.
(13) Kubanek, J.; Whalen, K. E.; Engel, S.; Kelly, S. R.; Henkel, T. P.;
Fenical, W.; Pawlik, J. R. Oecologia 2002, 131, 125-136.
(14) Kubanek, J.; Pawlik, J. R.; Eve, T. M.; Fenical, W. Mar. Ecol. Prog.
Ser. 2000, 207, 69-77.
(15) Kalinovsky, A. I.; Antonov, A. S.; Afiyatullov, S. S.; Dmitrenok, P
.S.; Evtuschenko, E. V.; Stonik, V. A. Tetrahedron Lett. 2002, 43,
523-525.
(16) Antonov, A. S.; Afiyatullov, S. S.; Kalinovsky, A. I.; Ponomasrenko,
L. P.; Dmitrenok, P. S.; Aminin, D. L.; Agafonova, I. G.; Stonik, V.
A. J. Nat. Prod. 2003, 66, 1082-1088.
(17) Fujioka, T.; Iwamoto, M.; Iwase, Y.; Okabe, H.; Mihashi, K.;
Yamachi, T. Chem. Pharm. Bull. 1988, 36, 2772-2777.